Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

William Sandborn

Gastroenterology San Diego, CA Medical Doctor

NPI 1639157563 CMS profile 164363

200 W Arbor Dr, San Diego, CA 92103

Open in the dashboard

General payments

$339,744

236 records reported · program years 2019–2023

Research payments

$94,822

Paid to them · 64 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,821,683 paid to institutions, not to them · program years 2019–2024

Through program year 2023, William Sandborn of San Diego, CA is reported in the CMS Open Payments database as having received $339,744 across 236 general payments and $94,822 in research payments paid to them. Separately, studies naming them as principal investigator received $1,821,683 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $20 1
2023 Research $6,000 3
2022 General $12,126 7
2022 Research $20,560 13
2021 General $54,717 32
2021 Research $30,020 21
2020 General $107,293 56
2020 Research $32,467 22
2019 General $165,589 140
2019 Research $5,775 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Sandborn
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to William Sandborn were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year William Sandborn Gastroenterology median Middle half National median
2019 $165,589 $417 $126–$1,100 $163
2020 $107,293 $224 $74–$624 $114
2021 $54,717 $352 $106–$1,054 $132
2022 $12,126 $448 $129–$1,270 $149
2023 $20 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Takeda Pharmaceuticals U.S.A., Inc. $77,677 33 payments
  2. Pfizer Inc. $34,792 19 payments
  3. Eli Lilly and Company $28,976 27 payments
  4. Celgene Corporation $26,845 8 payments
  5. E.R. Squibb & Sons, L.L.C. $24,552 12 payments
  6. AbbVie, Inc. $22,497 32 payments
  7. Genentech, Inc. $21,007 15 payments
  8. Janssen Biotech, Inc. $16,710 16 payments
  9. Celltrion, Inc. $16,706 3 payments
  10. Gilead Sciences, Inc. $10,466 18 payments
  11. Other $59,518 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $266,467 114 payments
  2. Travel and Lodging $30,874 36 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,413 18 payments
  4. Honoraria $11,600 3 payments
  5. Food and Beverage $5,390 65 payments
Products named General payments · program years 2019–2023
  1. STELARA $27,090 27 payments
  2. ZEPOSIA $22,950 5 payments
  3. Entyvio Lower GI $21,202 16 payments
  4. ENTYVIO Internal Medicine $20,483 10 payments
  5. XELJANZ $20,082 12 payments
  6. ORENCIA $9,586 5 payments
  7. HUMIRA $9,312 20 payments
  8. RINVOQ $8,660 6 payments
  9. XIFAXAN $5,401 2 payments
  10. SIMPONI ARIA $4,739 3 payments
  11. Other $8,700 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Pfizer Inc. $73,690 51 payments
  2. UCB, Inc. $10,020 5 payments
  3. E.R. Squibb & Sons, L.L.C. $6,738 2 payments
  4. AbbVie, Inc. $2,344 4 payments
  5. Celgene Corporation $2,030 2 payments

Records

300 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record